These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3458625)

  • 1. Targeting of anti-cancer therapeutic agents by monoclonal antibodies.
    Embleton MJ
    Biochem Soc Trans; 1986 Apr; 14(2):393-5. PubMed ID: 3458625
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
    Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
    Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
    Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
    Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
    Schadendorf D; Worm M; Algermissen B; Kohlmus CM; Czarnetzki BM
    Cancer; 1994 Jan; 73(1):103-8. PubMed ID: 7506115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
    Ma H; He C; Cheng Y; Yang Z; Zang J; Liu J; Chen X
    ACS Appl Mater Interfaces; 2015 Dec; 7(49):27040-8. PubMed ID: 26575336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antineoplastic activity of combinations of cytostatics and dextran-ferrite administered to mice with leukemia P-388].
    Brusentsov NA; Glazkova TIu; Iavorskaia NP; Iurchenko NIa
    Eksp Onkol; 1990; 12(6):59-60. PubMed ID: 2261881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of intraarterial chemotherapy for the treatment of osteogenic sarcoma in children].
    Glukhovskaia IIu
    Klin Khir; 1997; (2):12-4. PubMed ID: 9424277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived osteosarcoma cells are resistant to methotrexate.
    Dos Santos Cavalcanti A; Meohas W; Ribeiro GO; de Sá Lopes AC; Gholamin S; Razavi M; Hanae Kasai Brunswick T; Avan A; Matheus Guimarães JA; Leite Duarte ME; Kahn SA
    PLoS One; 2017; 12(9):e0184891. PubMed ID: 28934267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma?
    Lange B; Levine AS
    Cancer Treat Rep; 1982 Sep; 66(9):1699-704. PubMed ID: 6749284
    [No Abstract]   [Full Text] [Related]  

  • 12. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
    Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
    Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antineoplastic chemotherapy for bronchial carcinoma].
    Tanneberger S
    Arch Geschwulstforsch; 1985; 55(1):63-71. PubMed ID: 2985017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
    Dillman RO; Johnson DE; Ogden J; Beidler D
    Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of anti-idiotypic antibody-drug conjugates to treat experimental murine B-cell tumors.
    Hurwitz E; Haimovich J
    Methods Enzymol; 1989; 178():369-75. PubMed ID: 2601626
    [No Abstract]   [Full Text] [Related]  

  • 17. [Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
    Orthopade; 2013 Dec; 42(12):1072. PubMed ID: 24482827
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
    Weiner MA; Harris MB; Lewis M; Jones R; Sherry H; Feurer EJ; Johnson J; Lahman E
    Cancer Treat Rep; 1986 Dec; 70(12):1431-2. PubMed ID: 3466693
    [No Abstract]   [Full Text] [Related]  

  • 19. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
    Zhai L; Sun N; Han Z; Jin HC; Zhang B
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug therapy of malignant tumors of the bone and soft tissues].
    Abe M
    Nihon Seikeigeka Gakkai Zasshi; 1981 Dec; 55(12):1729-41. PubMed ID: 7037997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.